May 2007
Volume 48, Issue 13
ARVO Annual Meeting Abstract  |   May 2007
A Multicenter Evaluation of the Effect of Patient Education on Acceptance of Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension
Author Affiliations & Notes
  • S. Silverstein
    Silverstein Eye Centers, Kansas City, Missouri
  • T. Mundorf
    Mundorf Eye Center, Charlotte, North Carolina
  • R. Noecker
    University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
  • R. Craven
    Private practice, Littleton, Colorado
  • M. Earl
    IMEDS, Riverside, California
  • Footnotes
    Commercial Relationships S. Silverstein, None; T. Mundorf, Allergan, C; R. Noecker, Allergan, C; R. Craven, None; M. Earl, None.
  • Footnotes
    Support Funded by unrestricted grants
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 4824. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Silverstein, T. Mundorf, R. Noecker, R. Craven, M. Earl; A Multicenter Evaluation of the Effect of Patient Education on Acceptance of Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4824.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose:: The purpose of this study was to evaluate the incidence of hyperemia in patients using bimatoprost and to determine if simple interventions result in increased understanding of glaucoma and hyperemia.

Methods:: Multicenter, open-label, evaluator masked trial. Patients (n=64) were randomized to intervention (Group 1) or no intervention (Group 2). For Group 1, office staff were asked to review a fact sheet explaining the importance of IOP lowering and the efficacy of bimatoprost. Patients were given this sheet to take home. Group 2 was instructed only to instill bimatoprost daily and was given no additional instructions. Visits were at baseline, days 1 and 7, month 1, and week 6. At each study visit, patients completed a questionnaire about any hyperemia and how it affected their willingness to continue bimatoprost.

Results:: As graded by investigators, conjunctival hyperemia peaked 1 day after commencing bimatoprost, with a mean of 1.1 (0.5=trace, 1=mild, 2=moderate, 3=severe). By Day 7, hyperemia levels were approximately trace (0.69) and continued to decrease throughout the study. At each visit, patients in Group 2 were slightly more bothered by hyperemia than were patients in Group 1. At each visit, Group 1 was more likely than Group 2 to report that lowering IOP was very important to preserving vision (for example, at Day 7, 90% and 65%, respectively, P=.016). Group 1 was more likely than Group 2 to be willing to continue to use bimatoprost, despite hyperemia (97% vs. 88% at Day 1, P=.293).

Conclusions:: Overall, hyperemia peaked at day 1 (to mild levels) and quickly returned to baseline. Patients in Group 1 were more aware of the importance of IOP lowering and were more willing to tolerate hyperemia. Most patients were not bothered by hyperemia. Patient education can improve patient acceptance of a prescribed regimen and potentially increase compliance.

Clinical Trial:: NCT00348062

Keywords: clinical (human) or epidemiologic studies: biostatistics/epidemiology methodology • clinical (human) or epidemiologic studies: outcomes/complications • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.